VectivBio Holding AG (VECT) Stock Price, Forecast & Analysis
USA - NASDAQ:VECT - CH1109007893 - Common Stock
VECT Key Statistics, Chart & Performance
The current stock price of VECT is 16.85 USD. In the past month the price increased by 1.08%. In the past year, price increased by 186.54%.
VECT Latest News, Press Relases and Analysis
VECT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About VECT
Company Profile
VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. The company is headquartered in Basel, Basel-Stadt and currently employs 42 full-time employees. The company went IPO on 2021-04-09. The firm trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.
Company Info
VectivBio Holding AG
Aeschenvorstadt 36
Basel BASEL-STADT 22046 CH
Employees: 42
Phone: 41615513030.0
VectivBio Holding AG / VECT FAQ
Can you describe the business of VectivBio Holding AG?
VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. The company is headquartered in Basel, Basel-Stadt and currently employs 42 full-time employees. The company went IPO on 2021-04-09. The firm trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.
Can you provide the latest stock price for VectivBio Holding AG?
The current stock price of VECT is 16.85 USD.
Does VECT stock pay dividends?
VECT does not pay a dividend.
What is the ChartMill rating of VectivBio Holding AG stock?
VECT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is VECT stock listed?
VECT stock is listed on the Nasdaq exchange.
Would investing in VectivBio Holding AG be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VECT.
What is the expected growth for VECT stock?
The Revenue of VectivBio Holding AG (VECT) is expected to decline by -96.99% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
VECT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VECT. When comparing the yearly performance of all stocks, VECT is one of the better performing stocks in the market, outperforming 98.97% of all stocks.
VECT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VECT. The financial health of VECT is average, but there are quite some concerns on its profitability.
VECT Financial Highlights
Over the last trailing twelve months VECT reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.05 |
VECT Forecast & Estimates
8 analysts have analysed VECT and the average price target is 18.36 USD. This implies a price increase of 8.96% is expected in the next year compared to the current price of 16.85.
For the next year, analysts expect an EPS growth of 8.67% and a revenue growth -96.99% for VECT